JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258914

Human IFI44L knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

IFI44L KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp deletion in exon2.
2 Images
Sanger Sequencing - Human IFI44L knockout A549 cell lysate (AB258914)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFI44L knockout A549 cell lysate (AB258914)

Allele-2 : 1 bp insertion in exon2

Sanger Sequencing - Human IFI44L knockout A549 cell lysate (AB258914)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFI44L knockout A549 cell lysate (AB258914)

Allele-1 : 2 bp deletion in exon2

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2 and 2 bp deletion in exon2.

Disease

Carcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258914-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human IFI44L knockout A549 cell lysate", "number":"AB258914-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB258914-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IFI44L
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The interferon-induced protein 44-like (IFI44L) is a protein encoded by the IFI44L gene. It is also known as IFI44L protein or sometimes simply IFI44L. This protein has a molecular mass of around 49 kDa. IFI44L is broadly expressed in many tissues with higher expression in blood and spleen. Mechanically IFI44L contributes to the antiviral response by being induced by type I and type II interferons. Its exact mechanism of action involves modulation in response to viral infection although full details of how it works are still not completely understood.
Biological function summary

IFI44L plays an active role in the body's defense against viral infections. It participates as part of the broader immune response. While not being recognized as a classic element of a large protein complex it interacts with cellular machinery responsible for immune regulation and interferon signaling. This protein contributes towards the establishment of an antiviral state in affected cells through mechanisms which are yet to be completely defined. Its inducible nature makes it an important part of how cells respond to foreign viral components.

Pathways

This target connects to the interferon signaling pathway which is important for antiviral defenses. IFI44L plays a significant role in the broader cytokine signaling pathways particularly those related to type I interferon responses. It interacts with proteins such as MX1 and IFIT1 which are important elements of the interfacing network that responds to viral challenges in the cell. These relationships help in sustaining a robust antiviral state within the host.

IFI44L is linked to conditions like systemic lupus erythematosus (SLE) and viral infections such as hepatitis C. This can be due to its regulatory role in immune responses and interferon signaling. In SLE where interferon activity is often dysregulated IFI44L expression can be elevated. It also connects with proteins like IFI27 and ISG15 which are similarly upregulated in response to viral infections and are implicated in the pathogenesis of these diseases. Understanding IFI44L's function and interactions further aids in exploring therapeutic approaches for these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com